Soluble Vascular Endothelial Growth Factor Receptor 1 in Tracheal Aspirate Fluid of Preterm Neonates at Birth May Be Predictive of Bronchopulmonary Dysplasia/Chronic Lung Disease

被引:35
作者
Hasan, Jamal [1 ,2 ]
Beharry, Kay D. [1 ]
Valencia, Arwin M. [2 ]
Strauss, Arthur [2 ]
Modanlou, Houchang D. [1 ]
机构
[1] Univ Calif Irvine, Dept Pediat, Div Neonatol Perinatal Med, Irvine, CA 92717 USA
[2] Miller Childrens Hosp, Dept Pediat, Div Neonatol Perinatal Med, Long Beach, CA USA
关键词
bronchopulmonary dysplasia; chronic lung disease; preterm infants; vascular endothelial growth factor; PREMATURE BABOONS; EXPRESSION; HYPOXIA; HYPERTENSION; INJURY; ROLES; FLT-1;
D O I
10.1542/peds.2008-1670
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
OBJECTIVE. We tested the hypothesis that soluble vascular endothelial growth factor receptors are involved in the development of bronchopulmonary dysplasia/chronic lung disease. PATIENTS AND METHODS. Neonates with a birth weight of <= 1500 g and/or <= 30 weeks' gestation, with respiratory failure, requiring O-2 and mechanical ventilation within 24 hours, were eligible. Tracheal aspirate fluid samples were collected from 65 neonates before surfactant and/or assisted mechanical ventilation (baseline), at 3 and 7 days after birth, and weekly thereafter until extubation. Samples were analyzed for total vascular endothelial growth factor, soluble vascular endothelial growth factor receptor 1 and 2 levels and compared in infants with bronchopulmonary dysplasia/chronic lung disease (n = 31) versus those with no bronchopulmonary dysplasia/chronic lung disease (n = 34). RESULTS. Mean gestational age and birth weight were lower in infants with bronchopulmonary dysplasia/chronic lung disease. At baseline, vascular endothelial growth factor levels in the tracheal aspirate fluid were significantly lower, whereas soluble vascular endothelial growth factor receptor 1 levels were higher in the bronchopulmonary dysplasia/chronic lung disease infants compared with infants with no bronchopulmonary dysplasia/chronic lung disease. Vascular endothelial growth factor levels progressively increased from baseline to 4 weeks in all of the infants developing bronchopulmonary dysplasia/chronic lung disease. Conversely, soluble vascular endothelial growth factor receptor 1 declined in both groups from baseline to 5 weeks of age. Similarly, soluble vascular endothelial growth factor receptor 2 declined from baseline to 5 weeks in the control infants, but there were significant increases at 3 and 4 weeks in infants developing bronchopulmonary dysplasia/chronic lung disease. CONCLUSIONS. We speculate that low vascular endothelial growth factor levels in tracheal aspirate fluid, concurrent with elevated soluble vascular endothelial growth factor receptor 1 levels on the first day of life, are biological markers for the development of bronchopulmonary dysplasia/chronic lung disease in very low birth weight infants requiring O-2 and assisted mechanical ventilation. Pediatrics 2009; 123: 1541-1547
引用
收藏
页码:1541 / 1547
页数:7
相关论文
共 29 条
  • [1] Bronchopulmonary dysplasia - "A vascular hypothesis"
    Abman, SH
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (10) : 1755 - 1756
  • [2] Vascular endothelial growth factor gene expression in human fetal lung in vitro
    Acarregui, MJ
    Penisten, ST
    Goss, KL
    Ramirez, K
    Snyder, JM
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1999, 20 (01) : 14 - 23
  • [3] Peptide growth factors in tracheal aspirates of mechanically ventilated preterm neonates
    Ambalavanan, N
    Novak, ZE
    [J]. PEDIATRIC RESEARCH, 2003, 53 (02) : 240 - 244
  • [4] NEW BALLARD SCORE, EXPANDED TO INCLUDE EXTREMELY PREMATURE-INFANTS
    BALLARD, JL
    KHOURY, JC
    WEDIG, K
    WANG, L
    EILERSWALSMAN, BL
    LIPP, R
    [J]. JOURNAL OF PEDIATRICS, 1991, 119 (03) : 417 - 423
  • [5] Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia
    Bhatt, AJ
    Pryhuber, GS
    Huyck, H
    Watkins, RH
    Metlay, LA
    Maniscalco, WM
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (10) : 1971 - 1980
  • [6] A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation
    Clark, DE
    Smith, SK
    He, YL
    Day, KA
    Licence, DR
    Corps, AN
    Lammoglia, R
    Charnock-Jones, DS
    [J]. BIOLOGY OF REPRODUCTION, 1998, 59 (06) : 1540 - 1548
  • [7] Coalson JJ., 2000, LUNG BIOL HEALTH DIS, P85
  • [8] The role of vascular growth factors in hyperoxia-induced injury to the developing lung
    D'Angio, CT
    Maniscalco, WM
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2002, 7 : D1609 - D1623
  • [9] Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth, factor receptor-2 levels as a surrogate biomarker for tumor growth
    Ebos, John M. L.
    Lee, Christina R.
    Bogdanovic, Elena
    Alami, Jennifer
    Van Slyke, Paul
    Francia, Giulio
    Xu, Ping
    Mutsaers, Anthony J.
    Dumont, Daniel J.
    Kerbel, Robert S.
    [J]. CANCER RESEARCH, 2008, 68 (02) : 521 - 529
  • [10] Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia
    Ehrenkranz, RA
    Walsh, MC
    Vohr, BR
    Jobe, AH
    Wright, LL
    Fanaroff, AA
    Wrage, LA
    Poole, K
    [J]. PEDIATRICS, 2005, 116 (06) : 1353 - 1360